



2 November 2021  
2 November 2021  
P.U. (A) 412

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)  
(NO. 2) 2021

*POISONS (AMENDMENT OF POISONS LIST)  
(NO. 2) ORDER 2021*

DISIARKAN OLEH/  
*PUBLISHED BY*  
JABATAN PEGUAM NEGARA/  
*ATTORNEY GENERAL'S CHAMBERS*

## AKTA RACUN 1952

## PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2021

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Acebutolol; its salts” dan butir-butir yang berhubungan dengannya butir dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Aceclofenac	-	All preparations”;				

- (ii) dengan memotong butiran “Ambrisentan” dan butir-butir yang berhubungan dengannya;
- (iii) dengan memasukkan selepas butiran “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ambrisentan	-	All preparations”;				

- (iv) dengan memasukkan selepas butiran “Cilazapril” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cilnidipine	-	All preparations”;				

- (v) dengan memasukkan selepas butiran “Ectylurea” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Edaravone	-	All preparations”;				

- (vi) dengan menggantikan butiran “Ethchlorvynol” dengan butiran “Ethchlorvynol”;
- (vii) dengan menggantikan butiran “Glucose” dengan butiran “Glucose unless specified elsewhere in the List”;
- (viii) dalam senarai “Monoclonal antibody; includes the following:”—

- (A) dengan memasukkan selepas butiran “Brodalumab” butiran “Brolucizumab”;
- (B) dengan memasukkan selepas butiran “Rituximab” butiran “Romosozumab”; dan
- (C) dengan memasukkan selepas butiran “Secukinumab” butiran “Siltuximab”;

- (ix) dengan memasukkan selepas butiran “Ripasudil” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Risdiplam	-	All preparations”;				

- (x) dengan memotong butiran “Siltuximab” dan butir-butir yang berhubungan dengannya;

- (xi) dengan memasukkan selepas butiran “Simvastatin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Siponimod	-	All preparations”;				

(xii) dengan memasukkan selepas butiran “Succinylated gelatin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sucroferric oxyhydroxide	-	All preparations”;				

(xiii) dengan memasukkan selepas butiran “Terconazole” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Teriflunomide	-	All preparations”;			dan	

(xiv) dengan memasukkan selepas butiran “Tipepidine hybenzate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tipiracil	-	All preparations”; dan				

(b) dalam Lampiran kepada Senarai Racun—

- (i) dalam senarai “**Analgesics including antipyretic and anti-inflammatory agents:**”, dengan memasukkan sebelum butiran “Acetanilide; alkylacetanilides” butiran “Aceclofenac”;
- (ii) dalam senarai “**Antihypertensives:**”, dengan memasukkan selepas butiran “Cilazapril” butiran “Cilnidipine”;
- (iii) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—
  - (A) dengan memasukkan selepas butiran “Rituximab” butiran “Romosozumab”;
  - (B) dengan memasukkan selepas butiran “Simeprevir” butiran “Siponimod”; dan
  - (C) dengan memasukkan selepas butiran “Temsirolimus” butiran “Teriflunomide”;

- (iv) dalam senarai “**Hypnotics and sedatives:**”, dengan menggantikan butiran “Ethchlorvynol” dengan butiran “Ethchlorvynol”; dan
- (v) dalam senarai “**Miscellaneous:**”—
  - (A) dengan memasukkan selepas butiran “Brinzolamide” butiran “Brolucizumab”;
  - (B) dengan memasukkan selepas butiran “Dutasteride” butiran “Edaravone”;
  - (C) dengan menggantikan butiran “Glucose” dengan butiran “Glucose unless specified elsewhere in the List”;
  - (D) dengan memasukkan selepas butiran “Ripasudil” butiran “Risdiplam”;
  - (E) dengan memasukkan selepas butiran “Succinylated gelatin” butiran “Sucroferric oxyhydroxide”; dan
  - (F) dengan memasukkan selepas butiran “Tiludronic acid; its salts” butiran “Tipiracil”.

Dibuat 15 Oktober 2021  
[KKM.R.600-1/1/56; PN(PU2)172/XIX]

KHAIRY JAMALUDDIN ABU BAKAR  
*Menteri Kesihatan*

## POISONS ACT 1952

## POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2021

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 2) Order 2021**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

- (i) by inserting after the item “Acebutolol; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Aceclofenac	-	All preparations”;				

- (ii) by deleting the item “Ambrisentan” and the particulars relating to it;
- (iii) by inserting after the item “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ambrisentan	-	All preparations”;				

- (iv) by inserting after the item “Cilazapril” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cilnidipine	-	All preparations”;				

- (v) by inserting after the item “Ectylurea” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Edaravone	-	All preparations”;				

- (vi) by substituting for the item “Ethchlorvynol” the item “Ethchlorvynol”;
- (vii) by substituting for the item “Glucose” the item “Glucose unless specified elsewhere in the List”;
- (viii) in the list of “Monoclonal antibody; includes the following:”—

- (A) by inserting after the item “Brodalumab” the item “Brolucizumab”;
- (B) by inserting after the item “Rituximab” the item “Romosozumab”; and
- (C) by inserting after the item “Secukinumab” the item “Siltuximab”;

- (ix) by inserting after the item “Ripasudil” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Risdiplam	-	All preparations”;				

- (x) by deleting the item “Siltuximab” and the particulars relating to it;

(xi) by inserting after the item “Simvastatin” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Siponimod	-	All preparations”;				

(xii) by inserting after the item “Succinylated gelatin” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sucroferric oxyhydroxide	-	All preparations”;				

(xiii) by inserting after the item “Terconazole” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Teriflunomide	-	All preparations”;	and			

(xiv) by inserting after the item “Tipepidine hybenzate” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tipiracil	-	All preparations”; and				

(b) in the Appendix to the Poisons List—

- (i) in the list of “**Analgesics including antipyretic and anti-inflammatory agents:**”, by inserting before the item “Acetanilide; alkylacetanilides” the item “Aceclofenac”;
- (ii) in the list of “**Antihypertensives:**”, by inserting after the item “Cilazapril” the item “Cilnidipine”;
- (iii) in the list of “**Antineoplastic agents and Immunosuppressants:**”—
  - (A) by inserting after the item “Rituximab” the item “Romosozumab”;
  - (B) by inserting after the item “Simeprevir” the item “Siponimod”; and
  - (C) by inserting after the item “Temsirrolimus” the item “Teriflunomide”;

- (iv) in the list of “**Hypnotics and sedatives:**”, by substituting for the item “Ethchlorvynol” the item “Ethchlorvynol”; and
- (v) in the list of “**Miscellaneous:**”—
  - (A) by inserting after the item “Brinzolamide” the item “Brolucizumab”;
  - (B) by inserting after the item “Dutasteride” the item “Edaravone”;
  - (C) by substituting for the item “Glucose” the item “Glucose unless specified elsewhere in the List”;
  - (D) by inserting after the item “Ripasudil” the item “Risdiplam”;
  - (E) by inserting after the item “Succinylated gelatin” the item “Sucroferric oxyhydroxide”; and
  - (F) by inserting after the item “Tiludronic acid; its salts” the item “Tipiracil”.

Made 15 October 2021  
[KKM.R.600-1/1/56; PN(PU2)172/XIX]

KHAIRY JAMALUDDIN ABU BAKAR  
*Minister of Health*